Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

ProlyteORS, the flagship brand of Cipla Health Limited, welcomes the recent directive from the Food Safety and Standards ...

Eli Lilly ( NYSE: LLY) has partnered with India's Cipla to market its weight-loss medication Tirzepatide under a new brand in ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

Analysts believe that while the deal is positive, Cipla's share price is unlikely to see a fresh run-up, given the rise it ...

Stay up-to-date with the Cipla Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a ...

Cipla will market Eli Lilly’s diabetes and weight-loss drug Mounjaro as Yurpeak in India, enhancing accessibility and ...

Cipla enters obesity and diabetes drug market with Eli Lilly's tirzepatide 'Yurpeak'; Nuvama retains 'Hold' on Cipla stock, ...

Cipla shares drop 3.7% after Eli Lilly deal, but analysts see strong growth in India's obesity market—learn more about the ...

Brokerage firm Nuvama Institutional Equities believes Cipla, with its strong field force and distribution network, could ...

Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and ...

Cipla and Lilly partner to distribute Yurpeak (tirzepatide) in India for type 2 diabetes and weight management. Broader ...